These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8124835)

  • 1. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure.
    Matsumori A; Shioi T; Yamada T; Matsui S; Sasayama S
    Circulation; 1994 Mar; 89(3):955-8. PubMed ID: 8124835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells.
    Sato Y; Matsumori A; Sasayama S
    J Mol Cell Cardiol; 1995 Oct; 27(10):2265-73. PubMed ID: 8576941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial.
    Deswal A; Petersen NJ; Feldman AM; White BG; Mann DL
    Chest; 2001 Aug; 120(2):453-9. PubMed ID: 11502643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
    J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line.
    Shioi T; Matsumori A; Matsui S; Sasayama S
    Life Sci; 1994; 54(1):PL11-6. PubMed ID: 8255163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of cytokine inhibitors. A new therapeutic insight into heart failure.
    Matsumori A
    Int J Cardiol; 1997 Dec; 62 Suppl 1():S3-12. PubMed ID: 9464576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of vesnarinone on TNF alpha production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis.
    Jiang H; Bielekova B; Okazaki H; Clarence-Smith K; Johnson KP; Bergey G; Martin R; Dhib-Jalbut S
    J Neuroimmunol; 1999 Jun; 97(1-2):134-45. PubMed ID: 10408967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vesnarinone: a new inotropic agent for treating congestive heart failure.
    Cavusoglu E; Frishman WH; Klapholz M
    J Card Fail; 1995 Jun; 1(3):249-57. PubMed ID: 9420657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vesnarinone prolongs survival and reduces lethality in a murine model of lethal endotoxemia.
    Matsui S; Matsumori A; Sasayama S
    Life Sci; 1994; 55(22):1735-41. PubMed ID: 7968253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group.
    Feldman AM; Bristow MR; Parmley WW; Carson PE; Pepine CJ; Gilbert EM; Strobeck JE; Hendrix GH; Powers ER; Bain RP
    N Engl J Med; 1993 Jul; 329(3):149-55. PubMed ID: 8515787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of Chinese-made vesnarinone on experimental heart failure of dog].
    Du J; Yang Z
    Hua Xi Yi Ke Da Xue Xue Bao; 1992 Jun; 23(2):178-80. PubMed ID: 1452153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vesnarinone is a selective inhibitor of macrophage TNF(alpha) release.
    Kambayashi T; Mazurek N; Jacob CO; Wei N; Fong M; Strassmann G
    Int J Immunopharmacol; 1996; 18(6-7):371-8. PubMed ID: 9024938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).
    Deswal A; Petersen NJ; Feldman AM; Young JB; White BG; Mann DL
    Circulation; 2001 Apr; 103(16):2055-9. PubMed ID: 11319194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulation: a new horizon for medical treatment of heart failure.
    Sasayama S; Matsumori A; Matoba Y; Matsui S; Yamada T; Shioi T; Sato Y; Doyama K; Kishimoto C
    J Card Fail; 1996 Dec; 2(4 Suppl):S287-94. PubMed ID: 8951591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vesnarinone: a potential cytokine inhibitor.
    Sasayama S; Matsumori A
    J Card Fail; 1996 Sep; 2(3):251-8. PubMed ID: 8891863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Not Available].
    Matsumori A
    BioDrugs; 1997 Feb; 7(2):107-18. PubMed ID: 18031085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of vesnarinone on cytokine production and activation of murine microglia.
    Suzumura A; Sawada M
    Life Sci; 1999; 64(14):1197-203. PubMed ID: 10210262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of CD4 cross-linking-induced lymphocytes apoptosis by vesnarinone as a novel immunomodulating agent: vesnarinone inhibits Fas expression and apoptosis by blocking cytokine secretion.
    Oyaizu N; McCloskey TW; Than S; Pahwa S
    Blood; 1996 Mar; 87(6):2361-8. PubMed ID: 8630399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vesnarinone inhibits production of HIV-1 in cultured cells.
    Maruyama I; Maruyama Y; Nakajima T; Kitajima I; Osame M; Zhao JQ; Chen IS; Nakai S; Ikeda M; Yabu-uchi Y
    Biochem Biophys Res Commun; 1993 Sep; 195(3):1264-71. PubMed ID: 8216257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of vesnarinone, a quinolinone derivative, on the growth of leukemic blasts in acute myelogenous leukemia.
    Nara N; Kurokawa H; Tohda S; Tomiyama J; Nagata K; Tanikawa S
    Exp Hematol; 1997 Mar; 25(3):199-204. PubMed ID: 9091294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.